Nature CommunicationsMolecular BiologyPeer-reviewed journal article
CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro
Katharina E. MeijboomiD, Abbas Abdallah, Nicholas P. FordhamiD, Hiroko Nagase, Tomás RodrígueziD, Carolyn KrausiD, Tania F. GendroniD, Gopinath KrishnaniD, Rustam Esanov, Nadja S. Andrade, Matthew J. RybiniD, Melina Ramic, Zachary D. Stephens, Alireza EdrakiiD, Meghan BlackwoodiD, Aydan KahrimaniD, Nils HenningeriD, Jean‐Pierre KocheriD, Michael G BenatariD, Michael H. BrodskyiD, Leonard PetrucelliiD, Fen‐Biao GaoiD, Erik J. SontheimeriD, Robert H. BrowniD, Zane R. ZeieriD, Christian MuelleriD
Abstract
A hexanucleotide repeat expansion (HRE) consisting of GGGGCC24+ in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Both are fatal neurodegenerative diseases with no current approved treatments that significantly slow disease progression or extend life expectancy. Several hypotheses have emerged to explain how this HRE causes neuronal death, including C9ORF72 haploinsufficiency, sequestration of RNA-binding proteins in the nucleus, and production of dipeptide repeat proteins. In the present study we used a CRISPR/Cas9 gene-editing approach to remove the HRE from the C9ORF72 genomic locus, designing guide RNAs (gRNAs) flanking the HRE, and delivered Cas9 and gRNAs using adeno-associated virus serotype 9 (AAV9) vectors. Here, we demonstrate successful excision of the HRE in C9ORF72 in primary cortical neurons and brains of three mouse models containing the C9ORF72 expanded HRE (ranging from 500-600 repeats) as well as in patient-derived iPSC motor neurons and brain organoids (450 repeats). This resulted in a reduction of RNA foci, poly-dipeptides and haploinsufficiency, the major hallmarks of C9-ALS/FTD, making this an extremely attractive therapeutic approach to these diseases.
- organism: mouse
- organism: human
- assay: CRISPR screen
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: perturbation response prediction
- approach: experimental assay
- Citations
- 72
- FWCI
- 7.50
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Two therapeutic CRISPR/Cas9 gene editing approaches revert FTD/ALS cellular pathology caused by a C9orf72 repeat expansion mutation in patient derived cells
Maria Sckaff, Kamaljot Gill, … Claire Dudley Clelland·bioRxiv·May 21, 2022
- Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair
Nidaa A. Ababneh, Jakub Scaber, … Kevin Talbot·Human Molecular GeneticsPeer-reviewed·Jun 1, 2020
- CRISPR-Cas9 targeted deletion of the C9orf72 repeat expansion mutation corrects cellular phenotypes in patient-derived iPS cells
Mochtar Pribadi, Zhongan Yang, … Giovanni Coppola·bioRxiv·May 2, 2016
- A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS/FTD
T. X. McCallister, C. K. W. Lim, … T. Gaj·bioRxiv·Dec 12, 2023
- CRISPR/Cas9-mediated generation of a de novo C9ORF72 knock-in isogenic iPSC cell bank to model ALS and FTD
Niamh Louise O’Brien, Erin C. Hedges, … Sarah Mizielinska·bioRxiv·Nov 12, 2025
- Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo
Liam Kempthorne, Deniz Vaizoglu, … Adrian M. Isaacs·Nature CommunicationsPeer-reviewed·Jan 8, 2025